Torrent Pharmaceuticals
Torrent Pharmaceuticals Limited, commonly known as Torrent Pharma, is a prominent player in the global pharmaceutical industry, headquartered in Ahmedabad, India. Founded in 1959, the company has established a strong presence in various operational regions, including North America, Europe, and emerging markets across Asia and Africa. Specialising in the development, manufacturing, and marketing of a diverse range of generic and branded pharmaceuticals, Torrent Pharma focuses on therapeutic areas such as cardiovascular, central nervous system, and anti-infectives. The company is recognised for its commitment to quality and innovation, which has led to significant milestones, including a robust portfolio of over 200 products. With a strong market position, Torrent Pharmaceuticals has garnered accolades for its research and development capabilities, making it a trusted name in the industry. Its dedication to improving patient outcomes through affordable healthcare solutions sets it apart in a competitive landscape.
DitchCarbon Score
How does Torrent Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Torrent Pharmaceuticals's score of 1 is lower than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Torrent Pharmaceuticals's reported carbon emissions
In 2023, Torrent Pharmaceuticals reported significant carbon emissions, with total emissions amounting to approximately 4,480,000 kg CO2e. This figure includes about 3,310,000 kg CO2e from Scope 1 emissions and around 1,370,000 kg CO2e from Scope 2 emissions. The previous year, 2022, saw total emissions of about 126,926,000 kg CO2e, with Scope 1 emissions at approximately 28,009,000 kg CO2e and Scope 2 emissions at about 98,916,000 kg CO2e. In 2024, emissions are projected to increase, with Scope 1 emissions estimated at about 5,250,000 kg CO2e and Scope 2 emissions at approximately 1,520,000 kg CO2e. This upward trend raises concerns regarding the company's climate commitments, as there are currently no specified reduction targets or initiatives documented. Torrent Pharmaceuticals has not disclosed any specific climate pledges or science-based targets for emissions reduction, indicating a potential area for improvement in their sustainability strategy. As the pharmaceutical industry faces increasing scrutiny over environmental impacts, it is crucial for Torrent Pharmaceuticals to establish clear commitments to reduce their carbon footprint and enhance transparency in their climate actions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 28,072,000 | 00,000,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 2 | 96,026,000 | 00,000,000 | 0,000,000,000 | 0,000,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Torrent Pharmaceuticals is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
